FAD (Flavin Adenine Dinucleotide)
FAD is a redox-active coenzyme derived from riboflavin (vitamin B2) that serves as an essential electron carrier in mitochondrial energy production, fatty acid oxidation, and numerous enzymatic reactions throughout the body.
Overview
Flavin adenine dinucleotide (FAD) is one of the most important coenzymes in human biochemistry, functioning as a prosthetic group for a wide range of oxidoreductase enzymes known as flavoproteins. It is synthesized from riboflavin (vitamin B2) through a two-step process involving phosphorylation to FMN and subsequent adenylylation. FAD participates in critical metabolic pathways including the citric acid cycle, electron transport chain, and beta-oxidation of fatty acids.
FAD functions by cycling between its oxidized form (FAD) and reduced form (FADH2), accepting and donating electrons during enzymatic reactions. It serves as the cofactor for succinate dehydrogenase (Complex II) in the electron transport chain, linking the citric acid cycle directly to oxidative phosphorylation. FAD-dependent enzymes also play roles in amino acid catabolism, purine biosynthesis, and the detoxification of xenobiotics.
Research interest in FAD supplementation centers on conditions associated with riboflavin deficiency or impaired flavoprotein function. Studies have explored its role in migraine prevention, mitochondrial disorders, and age-related metabolic decline. FAD status is particularly relevant in individuals with genetic polymorphisms affecting the MTHFR enzyme, where adequate riboflavin and FAD levels may help maintain normal homocysteine metabolism and methylation capacity.
Mechanism of Action
Coenzyme Structure & Redox Chemistry
Flavin adenine dinucleotide (FAD) is a redox-active coenzyme composed of riboflavin (vitamin B2) linked to adenosine monophosphate (AMP) via a pyrophosphate bridge. FAD functions as a two-electron/two-proton carrier, cycling between oxidized (FAD), semiquinone (FADH·), and fully reduced (FADH2) states. This versatile redox chemistry enables it to serve as a cofactor for over 100 flavoenzymes catalyzing oxidation, reduction, dehydrogenation, and monooxygenation reactions (PMID: 24655016).
Mitochondrial Electron Transport Chain
FADH2 is a critical electron donor to the electron transport chain (ETC). Succinate dehydrogenase (Complex II) contains a covalently bound FAD that accepts electrons from succinate during the TCA cycle, passing them through iron-sulfur clusters to ubiquinone (CoQ10). Electron-transferring flavoprotein (ETF) and ETF-ubiquinone oxidoreductase shuttle electrons from fatty acid beta-oxidation and amino acid catabolism into the ETC at the CoQ level. These FAD-dependent entry points contribute to the proton gradient driving ATP synthesis (PMID: 20675419).
Key FAD-Dependent Enzymes
FAD is essential for monoamine oxidases (MAO-A and MAO-B), which oxidatively deaminate serotonin, dopamine, norepinephrine, and tyramine, regulating neurotransmitter turnover. Glutathione reductase requires FAD to regenerate reduced glutathione (GSH) from GSSG, a critical antioxidant defense mechanism. Methylenetetrahydrofolate reductase (MTHFR) uses FAD as a cofactor for the conversion of 5,10-methyleneTHF to 5-methylTHF, linking riboflavin status to folate metabolism and homocysteine regulation (PMID: 22113863).
Biosynthesis & Regulation
FAD is synthesized from riboflavin by sequential action of riboflavin kinase (producing FMN) and FAD synthase (adding AMP). Intracellular FAD levels regulate riboflavin kinase activity through product inhibition, maintaining flavocoenzyme homeostasis.
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Reported Effects
Bioavailability:: Evidence suggests that active forms like FAD may be more effective than simple riboflavin for individuals with specific genetic mutations (e.g., MTHFR).. Syntropic Benefits:: Most effective when paired with other mitochondrial supports like CoQ10 or NAD+ precursors.. Onset:: Users typically report feeling metabolic changes within 1-2 weeks of consistent supplementation.. Clinical Support:: Growing clinical interest in using redox cofactors to treat cardiac and metabolic dysfunctions.
- Evidence suggests that active forms like FAD may be more effective than simple riboflavin for individuals with specific genetic mutations (e.g., MTHFR).
- Most effective when paired with other mitochondrial supports like CoQ10 or NAD+ precursors.
- Users typically report feeling metabolic changes within 1-2 weeks of consistent supplementation.
- Growing clinical interest in using redox cofactors to treat cardiac and metabolic dysfunctions.
Safety Profile
Safety Profile: FAD (Flavin Adenine Dinucleotide)
Common Side Effects
- Generally very well tolerated as a naturally occurring coenzyme
- Mild gastrointestinal upset (nausea, bloating) with oral supplementation
- Yellow-orange discoloration of urine (harmless; due to riboflavin metabolism)
- Occasional mild headache
- Rare skin flushing or warmth sensation
- Mild photosensitivity with high-dose supplementation
Serious Adverse Effects
- Serious adverse effects are extremely rare at recommended supplemental doses
- Theoretical risk of pro-oxidant activity at very high doses (FAD participates in oxidative reactions)
- Allergic reactions (urticaria, rare anaphylaxis) with injectable formulations
- No documented cases of FAD toxicity in the published literature at supplemental doses
- Injectable FAD (used in some countries) carries standard injection-related risks: infection, phlebitis
Contraindications
- Known hypersensitivity to riboflavin (vitamin B2) or FAD preparations
- Caution with concurrent use of photosensitizing medications (FAD increases photosensitivity at high doses)
- No absolute contraindications established for oral supplementation at standard doses
- Injectable forms: standard injection contraindications (active infection at injection site, known allergy to excipients)
Drug Interactions
- Methotrexate: May compete with folate metabolism pathways; clinical significance at supplemental FAD doses is minimal
- Tetracyclines and other antibiotics: Riboflavin (FAD precursor) may reduce absorption of certain antibiotics; space dosing by 2 hours
- Tricyclic antidepressants (amitriptyline, imipramine): May reduce riboflavin/FAD levels by increasing metabolic turnover
- Phenobarbital and other barbiturates: Increase oxidative degradation of riboflavin; may reduce FAD availability
- Doxorubicin: FAD-dependent enzymes involved in doxorubicin metabolism; theoretical interaction
- Probenecid: May reduce riboflavin absorption, potentially affecting FAD synthesis
- Chlorpromazine: Structurally similar to riboflavin; may interfere with FAD-dependent reactions
Population-Specific Considerations
- Elderly: May benefit from supplementation due to decreased absorption and dietary intake of riboflavin; well tolerated
- Pediatric: Generally safe within recommended B2 intake levels; no specific FAD supplementation studies in children
- Pregnant/Lactating: Riboflavin is essential during pregnancy; FAD supplementation generally considered safe at appropriate doses; do not exceed recommended B2 intake without medical guidance
- Renal impairment: Water-soluble vitamin; excess excreted renally; safe in mild-moderate impairment; monitor in severe renal failure
- Migraine patients: FAD and riboflavin supplementation studied for migraine prophylaxis (400 mg riboflavin daily); generally well tolerated
- Riboflavin deficiency: FAD supplementation is rational therapy; monitor for adequacy of response and potential underlying malabsorption
Pharmacokinetic Profile
Molecular Structure
- Formula
- C27H33N9O15P2
- Weight
- 785.5 Da
- PubChem CID
- 643975
- Exact Mass
- 785.1571 Da
- LogP
- -5
- TPSA
- 356 Ų
- H-Bond Donors
- 9
- H-Bond Acceptors
- 20
- Rotatable Bonds
- 13
- Complexity
- 1560
Identifiers (SMILES, InChI)
InChI=1S/C27H33N9O15P2/c1-10-3-12-13(4-11(10)2)35(24-18(32-12)25(42)34-27(43)33-24)5-14(37)19(39)15(38)6-48-52(44,45)51-53(46,47)49-7-16-20(40)21(41)26(50-16)36-9-31-17-22(28)29-8-30-23(17)36/h3-4,8-9,14-16,19-21,26,37-41H,5-7H2,1-2H3,(H,44,45)(H,46,47)(H2,28,29,30)(H,34,42,43)/t14-,15+,16+,19-,20+,21+,26+/m0/s1
VWWQXMAJTJZDQX-UYBVJOGSSA-NSafety Profile
Common Side Effects
- Chromaturia:: A harmless but bright yellow-orange discoloration of urine is the most frequently reported effect.
- Digestive Discomfort:: Rare reports of mild nausea if taken on an empty stomach.
- Overstimulation:: Occasional reports of difficulty sleeping if taken too late in the evening due to increased ATP production.
References (3)
- [1]The role of NAD+ metabolism and its modulation of mitochondria in aging and disease
→ This review explores how essential cofactors like NAD+ and related redox molecules support mitochondrial health and homeostatic components like mitophagy to combat age-related decline.
- [2]Emerging strategies, applications and challenges of targeting NAD+ in the clinic
→ Researchers discuss the diverse roles of pyridine and flavin-related nucleotides in signaling pathways, epigenetic regulation, and energy homeostasis as clinical targets for aging.
- [3]Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial
→ Sub-study analysis indicates that boosting redox cofactors improves cardiac bioenergetics and clinical outcomes like ejection fraction in patients with heart failure.
Exenatide (Byetta/Bydureon)
Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used primarily as an antidiabetic medication for type 2 diabetes mellitus. It works by stimulati
Fadogia Agrestis
Fadogia Agrestis is a shrub native to Africa, traditionally used in herbal medicine as an aphrodisiac and for its purported testosterone-boosting properties. Th